Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes fasting during Ramadan: A meta-analysis

Key Points

• SGLT2 inhibitors may be safe for managing type 2 diabetes during Ramadan, but caution is advised due to less robust results.
• The meta-analysis suggests that while there is some efficacy in controlling blood sugar, further research is needed to validate these findings.
• Large multicenter randomized trials are essential to confirm safety, particularly for those at risk during fasting periods.
• Clinical decision-making may improve with comprehensive studies that provide clearer guidelines for using SGLT2 inhibitors during Ramadan.

Abstract